Skip to Main Content
Table 3—

Changes in GFR, systolic and diastolic BP, MABP, UAER, and blood glucose induced by intravenous injection of 75 μg clonidine in 16 hypertensive type 2 diabetic patients without overt nephropathy treatment with placebo or 5 mg isradipine retard

Before clonidineAfter clonidineMean difference (95% CI)P
GFR (ml · min−1 · 1.73 m−2    
 Placebo 102 99 3.7 (1.3 to 6.1) <0.01 
 5 mg isradipine retard 106 98 8.3 (2.5 to 14.2) <0.01 
Systolic BP (mmHg)     
 Placebo 151 130 21 (16 to 26) <0.001 
 5 mg isradipine retard 143 123 19 (15 to 24) <0.001 
Diastolic BP (mmHg)     
 Placebo 87 75 12 (9 to 14) <0.001 
 5 mg isradipine retard 80 73 7 (4 to 11) <0.001 
MABP (mmHg)     
 Placebo 108 94 15 (12 to 18) <0.001 
 5 mg isradipine retard 101 90 11 (8 to 15) <0.001 
Log (UAER) (μg/min)     
 Placebo 1.01 0.87 0.15 (−0.06 to 0.35) NS 
 5 mg isradipine retard 0.89 0.75 0.13 (0.02 to 0.25) <0.05 
Blood glucose (mmol/l)     
 Placebo 9.1 9.5 −0.4 (−2.0 to 1.2) NS 
 5 mg isradipine retard 9.3 9.9 −0.6 (−1.7 to 0.5) NS 
Before clonidineAfter clonidineMean difference (95% CI)P
GFR (ml · min−1 · 1.73 m−2    
 Placebo 102 99 3.7 (1.3 to 6.1) <0.01 
 5 mg isradipine retard 106 98 8.3 (2.5 to 14.2) <0.01 
Systolic BP (mmHg)     
 Placebo 151 130 21 (16 to 26) <0.001 
 5 mg isradipine retard 143 123 19 (15 to 24) <0.001 
Diastolic BP (mmHg)     
 Placebo 87 75 12 (9 to 14) <0.001 
 5 mg isradipine retard 80 73 7 (4 to 11) <0.001 
MABP (mmHg)     
 Placebo 108 94 15 (12 to 18) <0.001 
 5 mg isradipine retard 101 90 11 (8 to 15) <0.001 
Log (UAER) (μg/min)     
 Placebo 1.01 0.87 0.15 (−0.06 to 0.35) NS 
 5 mg isradipine retard 0.89 0.75 0.13 (0.02 to 0.25) <0.05 
Blood glucose (mmol/l)     
 Placebo 9.1 9.5 −0.4 (−2.0 to 1.2) NS 
 5 mg isradipine retard 9.3 9.9 −0.6 (−1.7 to 0.5) NS 
Close Modal

or Create an Account

Close Modal
Close Modal